ISTP, 4901 Searle Parkway, Skokie, Il 60077

Exicure: Nasdaq Uplisting

Exicure (XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, reported financial results for 2Q 2019 & an update on corporate progress.

2Q 2019 Progress & Recent Developments

Announced important preclinical data supporting development of SNA technology in the central nervous system (CNS)

Expanded Board with experienced biotechnology leaders

AST-008 Phase 1b/2 clinical trial continues to progress—AST-008 is an SNA consisting of toll-like receptor 9 agonists designed for immuno-oncology applications.

Enhanced Financial Resources
• Up-listed from the OTC to the Nasdaq Capital Market.
• Closed oversubscribed underwritten public offering of 31,625,000 shares of common stock
• Insider participation of approximately $2.6 M

“The first half of 2019 continued to bring advancements across our pipeline,” said Dr. David Giljohann, Exicure’s chief executive officer. “We are extremely pleased with the strong progress in both our neurology and oncology franchises, while we simultaneously strengthened our board leadership and balance sheet. Our non-human primate data confirmed our enthusiasm for neurological applications of our SNA platform. Our recent $63.3 million public offering, which closed on August 2, 2019 provides the financial resources to advance these opportunities,” he added.

For the entire announcement, click here.

Comments Off on Exicure: Nasdaq Uplisting News

Read more

Exicure adds new sites

Exicure has added four new clinical trial sites for its Phase Ib/II trial of AST-008 for the treatment of various cancer types.   The sites are based in the US, including Dana Farber Cancer Institute in Massachusetts, Holden Comprehensive Cancer Center at the University of Iowa, John Wayne Cancer Institute at Providence St John’s Health Center in California, and Sylvester Comprehensive Cancer Center at the University of Miami in Florida.

Exicure CEO Dr David Giljohann said: “We are encouraged by the results of our Phase I clinical trial, which demonstrated that our drug is well-tolerated and activates key immune cells and signals.”

The initial stage of the open-label Phase Ib/II trial includes a dose-finding Phase Ib stage, where AST-008 is expected to be evaluated in combination with an anti-PD-1 therapy pembrolizumab (Keytruda). The Phase Ib stage is set to be followed by a Phase II expansion stage.

Exicure aims to enroll patients with superficial injectable tumours as part of the Phase Ib portion of the trial.  For more on this update, click here. 

Comments Off on Exicure adds new sites News

Read more